NMN and NR Side Effects: Rare but Serious Adverse Events Women Should Know

What "Rare but Serious" Means for a Dietary Supplement Like NMN or NR

Rare serious adverse events from supplements are harder to track than those from prescription drugs. NMN and NR are sold as dietary supplements in the United States, meaning they bypass the pre-market clinical trial requirements that drugs must meet. The FDA does not require manufacturers to prove safety before sale. Reports of harm reach the public mainly through the FDA Adverse Event Reporting System (FAERS), published case reports, and the small number of randomized controlled trials that have been completed.

The honest picture: the human trial database for NMN and NR is thin. As of mid-2025, fewer than 15 published placebo-controlled trials have evaluated either compound in humans, and most ran for 12 weeks or less. No trial has followed participants for more than one year. That absence of long-term data is not reassurance; it is an evidence gap.

How Women Differ From the Average Trial Participant

Most early NMN/NR pharmacokinetic studies enrolled predominantly male or mixed-sex cohorts without sex-stratified reporting. Nicotinamide metabolism involves the enzyme NNMT (nicotinamide N-methyltransferase), and NNMT expression differs by sex and changes across the menstrual cycle and with estrogen status. This means a postmenopausal woman metabolizing NMN may have a meaningfully different pharmacokinetic profile than a 35-year-old man, yet we do not have the data to quantify that difference precisely.

Women with PCOS already have altered NAD+ metabolism linked to insulin resistance, and those taking hormonal contraceptives may have shifts in tryptophan-to-NAD+ conversion that could interact with high-dose nicotinamide loading. These interactions remain uncharacterized.

Liver Enzyme Elevations: The Most Documented Serious Signal

The clearest serious adverse signal from NAD+ precursors involves the liver. This applies more directly to high-dose niacin (nicotinic acid) and high-dose nicotinamide (niacinamide) than to NMN or NR at typical supplement doses, but the metabolic pathway overlaps enough that hepatotoxicity cannot be dismissed.

Why the Liver Is Vulnerable

NMN and NR are both converted to nicotinamide in the gut and liver before entering the NAD+ salvage pathway. At doses above approximately 3,000 mg/day of any nicotinamide-form precursor, hepatotoxicity has been documented in case series and is reflected in the FDA's drug label for prescription niacin. Consumer NMN doses of 500 to 1,000 mg/day produce plasma nicotinamide concentrations that are substantially lower than those dangerous thresholds, but the ceiling is unknown for individuals with pre-existing liver disease.

What the Trials Show

In the Igarashi et al. 2023 trial, 250 mg/day of NMN for 12 weeks in postmenopausal women produced no statistically significant change in ALT, AST, or bilirubin versus placebo. A Chromadex-funded NR trial (Martens et al., 2018) similarly reported no liver enzyme signal at 1,000 mg/day NR over 6 weeks in healthy adults, though the sample was small (n=120) and the duration short.

The gap: no trial has screened specifically for elevated liver enzymes in women with non-alcoholic fatty liver disease (NAFLD), which affects approximately 25% of adult women globally and is strongly associated with PCOS and perimenopause-related metabolic shifts. If you have NAFLD, use NMN or NR only with baseline and follow-up liver function testing.

Practical Monitoring Guidance

• Obtain a baseline comprehensive metabolic panel (CMP) before starting.
• Repeat at 8 to 12 weeks if using doses at or above 500 mg/day.
• Stop and contact your provider if you develop right-upper-quadrant discomfort, jaundice, or unexplained fatigue.

Blood Pressure Changes: Understudied in Women

Two human studies have raised a blood pressure signal that warrants attention, particularly for women, who are more likely than men to experience white-coat hypertension and whose cardiovascular risk profile shifts dramatically after menopause.

The Data

A 2022 phase 1 trial of NMN (NCT03151239) in healthy adults reported small but statistically significant reductions in diastolic blood pressure at doses of 500 mg/day and above. Blood pressure lowering sounds favorable, but in women who are already on antihypertensive therapy, or in those with orthostatic hypotension (common in perimenopause), additive drops could cause syncope or falls.

Conversely, the Chromadex-funded Conze et al. 2019 NR study observed no significant blood pressure change at 300 mg/day NR over 8 weeks, suggesting dose may be the determining variable.

The Menopause Connection

Postmenopausal women have a steeper cardiovascular risk trajectory than age-matched men. The Menopause Society's 2023 position statement on cardiovascular risk emphasizes careful blood pressure management in this group. Any supplement producing even modest hemodynamic changes should be used cautiously alongside antihypertensives such as amlodipine, lisinopril, or metoprolol.

If you take any blood pressure medication, check your blood pressure at home for the first four weeks after starting NMN or NR.

Theoretical Cancer-Promotion Risk: What the Evidence Actually Says

This is the adverse event that generates the most anxiety online, and the evidence is genuinely uncertain.

The Biological Concern

NAD+ is required for DNA repair enzymes (PARPs) and sirtuins. Raising systemic NAD+ could theoretically support tumor cell survival because cancer cells have high metabolic demands and use NAD+ intensively. Preclinical data from Rajman et al. (2018) in Cell Metabolism noted that NAD+ repletion accelerated melanoma progression in mouse models, a finding that attracted significant concern.

Why This Matters More for Some Women

Breast cancer and ovarian cancer are hormonally sensitive and metabolically active cancers with high NAD+ demand. Women with a personal or family history of hormone-receptor-positive breast cancer, BRCA1/2 mutations, or Lynch syndrome (which increases ovarian and endometrial cancer risk) have a theoretical reason to discuss NAD+ precursor use with their oncologist before starting.

This is not a proven human risk. No clinical trial in humans has demonstrated NMN or NR causing cancer. The concern is mechanistic and preclinical. But because the supplement is unregulated and women with cancer histories are a substantial consumer group for anti-aging supplements, this disclosure is necessary.

A practical framework for women considering NMN or NR:

| Risk Profile | Recommendation | |---|---| | No cancer history, no active cancer | May use with monitoring; discuss with provider | | Personal history of hormone-receptor-positive breast cancer | Discuss with oncologist before use; avoid until cleared | | BRCA1/2 carrier, no active cancer | Discuss with oncologist; evidence is insufficient to prohibit | | Active cancer on treatment | Avoid without explicit oncologist approval | | Ovarian or endometrial cancer history | Discuss with gynecologic oncologist |

Flushing and Niacin-Equivalent Reactions

High-dose NR can produce niacin-like flushing, a prostaglandin-mediated vasodilatory reaction causing redness, warmth, and itching of the skin. This is rarely dangerous but can be alarming and has been mistaken for anaphylaxis in case reports submitted to poison control centers.

In the Martens et al. 2018 trial, flushing occurred in 4 of 60 participants receiving 1,000 mg/day NR. NMN is less likely to produce flushing because its conversion to free nicotinamide is more limited, but high-dose oral NMN (above 900 mg/day) may still produce mild flushing in sensitive individuals.

Women in perimenopause who already experience vasomotor symptoms (hot flashes, night sweats) may find it difficult to distinguish supplement-induced flushing from their underlying vasomotor symptoms. This confounding effect can delay recognition of the drug-related reaction.

Pregnancy and Lactation Safety: Avoid Both

This section is mandatory. The answer is direct: do not use NMN or NR during pregnancy or breastfeeding.

Pregnancy

There is no published human safety data on NMN or NR in pregnancy. Animal studies using high-dose nicotinamide (a downstream metabolite of both NMN and NR) have shown developmental toxicity at supraphysiologic doses in rodent models. NMN and NR have not been assigned a formal FDA pregnancy category because they are dietary supplements rather than drugs, but the absence of a category does not mean safety.

The developing fetus has active NAD+ biosynthesis requirements, and dysregulation of NAD+ during embryogenesis is associated with congenital malformations in animal models. Both insufficient and excessive NAD+ signaling appear harmful in preclinical data. Translating this to a safe human dose in pregnancy is not possible with current evidence.

ACOG's guidance on dietary supplements in pregnancy advises against use of any supplement without established human safety data. NMN and NR do not meet that bar.

Lactation

No studies have measured NMN or NR transfer into human breast milk. Nicotinamide does transfer into breast milk, and is present at approximately 0.4 to 1.8 mg per 100 mL of mature human milk at physiologic concentrations. Whether supplemental doses of NMN or NR meaningfully raise breast milk nicotinamide concentration is unknown. Until that data exists, supplemental NMN and NR should be avoided while breastfeeding.

Contraception Requirement

NMN and NR are not teratogens with a formal contraception requirement equivalent to isotretinoin or valproate. But given the preclinical developmental toxicity signals, women of reproductive age who are not planning pregnancy should use effective contraception and discontinue NMN or NR at least 4 to 8 weeks before attempting conception, purely as a precautionary measure until human reproductive safety data becomes available.

Who This Is Right For (and Who Should Avoid It)

Women Who Might Reasonably Consider NMN or NR

• Postmenopausal women with confirmed NAD+ decline seeking evidence-adjacent support for metabolic health, with provider supervision and baseline labs. This is the group with the most human trial data.
• Women with clinically confirmed mitochondrial dysfunction or documented NAD+ deficiency (rare conditions where the risk-benefit calculus may shift).
• Women participating in an IRB-approved clinical trial.

Women Who Should Avoid or Discuss Carefully First

• Pregnant or breastfeeding women. No use.
• Women trying to conceive. Pause use until more data emerges.
• Women with active liver disease, or ALT/AST above twice the upper limit of normal.
• Women with a personal history of any NAD+-dependent cancer (particularly breast, ovarian, or endometrial cancer).
• Women taking warfarin. High-dose nicotinamide metabolites may modestly potentiate warfarin anticoagulation; INR monitoring is warranted.
• Women with orthostatic hypotension or who are on multiple antihypertensives.

PCOS and Perimenopause

Women with PCOS have altered tryptophan-to-NAD+ metabolism and often have concurrent insulin resistance and NAFLD. The metabolic rationale for NAD+ precursors in PCOS is theoretically plausible, but no published RCT has evaluated NMN or NR specifically in women with PCOS. Any use in this group is extrapolated from general metabolic data, and that extrapolation should be named plainly to patients.

Perimenopausal women represent a rapidly growing consumer group for these supplements. Skeletal muscle NAD+ concentration decreases by approximately 30% between ages 45 and 60, which forms the rationale for supplementation in midlife women. The Igarashi 2023 postmenopausal trial is the closest to this demographic, but 12 weeks of data in 30 women per arm is insufficient to draw strong safety conclusions.

Drug Interactions With Medications Common in Women

Women are more likely than men to be prescribed certain drug classes that interact with nicotinamide metabolism.

Key Interactions

Hormonal contraceptives and HRT. Estrogen modulates the kynurenine pathway, which is a major route of endogenous NAD+ synthesis from tryptophan. Women on combined oral contraceptives may have lower baseline NAD+ due to estrogen-mediated upregulation of kynurenine aminotransferases, potentially making them more responsive to NAD+ precursors. This is pharmacologically interesting but not yet clinically actionable.

Chemotherapy agents. PARP inhibitors such as olaparib (used in BRCA-mutant ovarian and breast cancer) work partly by depleting NAD+. Concurrent NMN or NR use could theoretically blunt PARP inhibitor efficacy. Women on PARP inhibitors must not use NMN or NR without oncologist approval.

Antidiabetic drugs. Metformin, which is used in both type 2 diabetes and PCOS, may reduce mitochondrial NAD+ availability through complex I inhibition. Concomitant NAD+ precursor use in metformin users has not been studied in a controlled trial, and the interaction direction is unclear.

Isoniazid. Prescribed for tuberculosis, isoniazid inhibits NAD+ synthesis. Women on isoniazid might theoretically benefit from NAD+ precursors, but dosing guidance does not exist.

FAERS Reports and Post-Market Surveillance

The FDA's FAERS database receives voluntary adverse event reports for dietary supplements under a separate MedWatch pathway. As of the most recent publicly searchable quarter, NMN and NR have accumulated a small number of FAERS reports. Categories include gastrointestinal disturbance (most common), flushing, palpitations, and insomnia. Hepatotoxicity reports are rare but present.

FAERS is subject to massive underreporting bias for supplements. Consumers rarely associate a supplement with a serious event and even more rarely file a formal report. The actual adverse event rate is almost certainly higher than FAERS suggests. Women who experience a serious or unexpected adverse event while taking NMN or NR can file a report directly at FDA MedWatch.

The FDA's 2022 letter stating that NMN does not qualify as a lawful dietary ingredient under the New Dietary Ingredient (NDI) notification pathway because it was investigated as a drug before being marketed as a supplement adds regulatory uncertainty. This does not mean NMN is illegal to sell, but it does mean the FDA has flagged it for additional scrutiny, and the agency could act to remove it from the market.

The Evidence Gap: Honesty Is Part of Safety

Women have been systematically underrepresented in NAD+ precursor trials. The largest NMN trial in women (Igarashi 2023) enrolled 30 women per arm for 12 weeks. No trial has specifically evaluated NMN or NR in women with PCOS, endometriosis, or active perimenopause with concurrent hormone therapy. No trial has followed women for longer than 12 weeks.

This is not a reason to assume the supplements are dangerous. It is a reason to resist the marketing claim that these are proven safe for long-term use in women. The data to make that claim does not exist. What exists is a plausible biological mechanism, short-term tolerability data from small trials, and a theoretical serious adverse event profile that warrants clinical respect.

If you choose to use NMN or NR, the most prudent approach is the lowest effective dose (the 250 mg/day dose in the Igarashi trial is the best-studied dose in women), baseline and follow-up liver function testing, blood pressure monitoring for the first four weeks, and a provider who knows you are taking it.